Company Announcement
- Genmab to receive USD 30 million milestone payment from Janssen
- Milestone triggered by first commercial sale of DARZALEX in Europe
COPENHAGEN, Denmark, May 30, 2016 (GLOBE NEWSWIRE) -- Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has
achieved a USD 30 million milestone in its DARZALEX(r) (daratumumab) collaboration with Janssen Biotech, Inc.
(Janssen). The milestone payment was triggered by the first commercial sale of DARZALEX in Europe. The European Commission
(EC) recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX(r) (daratumumab) for use
as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a
proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last
therapy.
"We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and
launch DARZALEX in Europe," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
This milestone was included in Genmab's previously issued financial guidance for 2016.
About DARZALEX(r) (daratumumab)
DARZALEX(r) (daratumumab) injection for intravenous infusion is indicated in the United States for the treatment of patients with
multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an
immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1DARZALEX is the first
monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is
indicated in Europe for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose
prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last
therapy. For more information, visit www.DARZALEX.com.
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly
expressed on the surface of multiple myeloma cells. It is believed to induce rapid tumor cell death through programmed cell death,
or apoptosis,1,2 and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity,1,2
antibody-dependent cellular phagocytosis3,4 and antibody-dependent cellular cytotoxicity.1,2 In
addition, daratumumab therapy results in a reduction of immune-suppressive myeloid derived suppressor cells (MDSCs) and subsets of
regulatory T cells (Tregs) and B cells (Bregs), all of which express CD38. These reductions in MDSCs, Tregs and Bregs were
accompanied by increases in CD4+ and CD8+ T cell numbers in both the peripheral blood and bone marrow.1
Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and
commercialize daratumumab from Genmab. Five Phase III clinical studies with daratumumab in relapsed and frontline settings are
currently ongoing, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant
diseases on which CD38 is expressed, such as smoldering myeloma, non-Hodgkin's lymphoma and a solid tumor.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated
antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra(r)
(ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX(r) (daratumumab) for the treatment
of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma
indications and for non-Hodgkin's lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody technologies - the DuoBody(r) platform for
generation of bispecific antibodies, and the HexaBody(r) platform which creates effector function enhanced antibodies. The
company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has
alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future
results or performance expressed or implied by such statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes
and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks,
please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless
required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the Y-shaped Genmab logo(r); Genmab
in combination with the Y-shaped Genmab logo(tm); the DuoBody logo(r); the HexaBody logo(tm); HuMax(r);
HuMax-CD20(r); DuoBody(r); HexaBody(r) and UniBody(r). Arzerra(r) is a
trademark of Novartis AG or its affiliates. DARZALEX(r) is a trademark of Janssen Biotech, Inc.
1 DARZALEX Prescribing Information, November 2015.
2 De Weers, M, et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple
Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.
3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic
antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-321.
4 Khagi, Y and Mark, TM. Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther.
2014; 7: 1095-1100.
Company Announcement no. 26
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
